Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique
Bastard M, Molfino L, Mutaquiha C, Galindo MA, Zindoga P, Vaz D, Mahinça I, DuCros P, et al. (10 authors)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019-10
Abstract
Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.
MeSH terms
- Humans
- Tuberculosis, Multidrug-Resistant
- Kanamycin
- Antitubercular Agents
- Treatment Outcome
- Drug Administration Routes
- Injections
- Drug Administration Schedule
- Adult
- Middle Aged
- Mozambique
- Female
- Male
- Drug Substitution
- Diarylquinolines